Stockscreener 앱 받기
2.30
4.55%
0.10
시간 외 거래:
2.30
전일 마감가:
$2.20
열려 있는:
$2.2189
하루 거래량:
86,150
Relative Volume:
0.58
시가총액:
$12.90M
수익:
$14.58M
순이익/손실:
$-12.57M
주가수익비율:
-0.4049
EPS:
-5.68
순현금흐름:
$-13.07M
1주 성능:
+5.02%
1개월 성능:
-36.11%
6개월 성능:
-12.55%
1년 성능:
-12.88%
1일 변동 폭
$2.2189
$2.40
1주일 범위
$1.98
$2.40
52주 변동 폭
$1.91
$6.28
비보스 테라퓨틱스 Stock (VVOS) Company Profile
명칭
Vivos Therapeutics Inc
전화
(866)908-4867
주소
7921 SOUTHPARK PLAZA,, LITTLETON
VVOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
2.30 | 12.90M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
비보스 테라퓨틱스 주식(VVOS)의 최신 뉴스
Vivos Therapeutics to acquire operating assets of The Sleep Center of Nevada - MSN
Healthcare Stocks Take A Hit Despite Abbott's Earnings Beat - Finimize
Vivos Therapeutics to Acquire The Sleep Center of Nevada - marketscreener.com
Vivos Opens New Sleep Center - Baystreet.ca
Vivos Therapeutics announces agreement to acquire operating assets of SCN - TipRanks
Vivos To Acquire Operating Assets Of The Sleep Center Of Nevada - Nasdaq
Vivos Therapeutics Signs Definitive Agreement To Acquire Largest Sleep Center Operator In Nevada - marketscreener.com
Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada - The Manila Times
Major Healthcare Expansion: Vivos Takes Over Nevada Sleep Giant Serving 3,000 Monthly Patients - Stock Titan
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update - MSN
Commonwealth Equity Services LLC Buys 5,000 Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) - Defense World
Positive Sentiment Still Eludes Vivos Therapeutics, Inc. (NASDAQ:VVOS) Following 26% Share Price Slump - simplywall.st
Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress - ACCESS Newswire
Vivos Therapeutics Inc (VVOS) Q4 2024 Earnings Call Highlights: Strategic Shifts Propel Revenue ... By GuruFocus - Investing.com Canada
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vivos Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Vivos Therapeutics’ Earnings Call Highlights Growth and Expansion - TipRanks
Vivos Therapeutics (VVOS) Grows Revenue by 26% and Cuts Operatin - GuruFocus
Vivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global Partners - TipRanks
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Reports Revenue Growth and Strategic Shift - TipRanks
Vivos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Vivos Therapeutics Q4 2024 revenue rises 9% By Investing.com - Investing.com UK
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update - TradingView
Vivos Earnings: Revenue Jumps 9% as FDA Approves Game-Changing Pediatric Sleep Apnea Treatment - Stock Titan
Vivos Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Decline in Short Interest - Defense World
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - The Manila Times
Medical Device Innovator Vivos Sets Key Earnings Date: What to Watch in 2024 Results - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
The Silent Epidemic: How Women With Obstructive Sleep Apnea (OSA) Are Often Misdiagnosed - Yahoo Finance
Vivos Therapeutics (VVOS) Projected to Post Quarterly Earnings on Thursday - Defense World
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update - Defense World
Vivos Drives Innovation in Chronic Pain Care with Non-Invasive Treatment for Sleep Apnea - PRWeb
Anti-Snoring Devices Markets: Oral Appliances, Nasal - GlobeNewswire
Anti-Snoring Devices Markets: Oral Appliances, Nasal Devices, Position Control DevicesGlobal Forecast to 2029 with ResMed, SomnoMed, ProSomnus, and Vivos Therapeutics, and DynaFlex Dominating - Yahoo Finance UK
Comparing Vivos Therapeutics (NASDAQ:VVOS) and Regenicin (OTCMKTS:RGIN) - Armenian Reporter
Vivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center - marketscreener.com
Vivos Explores ‘Outright Acquisitions of Sleep Centers’ - Sleep Review
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance - Proactive Investors UK
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide - The Manila Times
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and - EIN News
Reviewing Vivos Therapeutics (NASDAQ:VVOS) & Biostage (OTCMKTS:BSTG) - Defense World
Vivos Therapeutics Inc to Host Earnings Call - ACCESS Newswire
Vivos Therapeutics to participate in Fireside Chat with Water Tower Research - Proactive Investors UK
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm - EIN News
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET. - The Globe and Mail
Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding - Simply Wall St
Vivos Therapeutics Enters Into At The Market Offering Agreement with H.C. Wainwright & Co., LLC**Littleton, Colo. – Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced on February 14, 2025, that the company has entered into an At The Market Offering - Defense World
Vivos Therapeutics Enters Market Offering Agreement with Wainwright - TipRanks
비보스 테라퓨틱스 (VVOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
자본화:
|
볼륨(24시간):